NCT07612449 · NOT YET RECRUITING

Percepta for Cognitive Optimization

This trial is testing a dietary supplement called Percepta, made from cat's claw bark extract and oolong tea extract, to see whether it improves cognitive performance in adults aged 40-85 with self-reported mild cognitive impairment. Participants take the supplement or a placebo daily for 6 months. Described as Phase 1, this is an early-stage feasibility study — it is not testing a proven or approved treatment.

You may qualify if

  • Demographics: Must be English-speaking and currently residing in the United States.
  • Cognitive Status: Must have self-reported cognitive impairment, defined specifically by a Montreal Cognitive Assessment (MoCA) score of less than 25.
  • Technology Access: Must own an Oura Ring, maintain an active membership throughout the study, and have consistent access to a smartphone for app-based surveys and data syncing.
  • Medical Stability: Must be in good general health and medically stable, with no significant health changes in the three months prior to enrollment.
  • Consent and Compliance: Must provide signed informed consent and demonstrate a willingness to comply with all study procedures, including assessments and lifestyle considerations.

You're excluded if

  • Neurological and Psychiatric Disorders: A self-reported diagnosis of dementia, Alzheimer's disease, Parkinson's disease, depressive disorders, bipolar disorder, schizophrenia, epilepsy, multiple sclerosis, or substance use disorder. This also includes a history of stroke, traumatic brain injury (TBI), intracranial hemorrhage, or seizure disorders.
  • Medication Use: Current use of cognitive-affecting medications or supplements, such as donepezil, memantine, methylphenidate, benzodiazepines, antipsychotics, or nootropics.
  • Allergies: Known allergy or sensitivity to cat's claw or oolong tea,. Reproductive Status: Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
  • Genetic Risk: Known carrier of the APOE-4 allele.
  • Recent Study Participation: Enrollment in another clinical trial or intervention study within the past 30 days.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-05-28

View full record on ClinicalTrials.gov

All APOE4 clinical trials